October 17 20, 2018 New York City. An International Congress on Lymphoma, Myeloma, and Leukemia Disorders

Transcription

1 An International Congress on Lymphoma, Myeloma, and Leukemia Disorders NEW DAY! New Approaches in Acute Leukemias and Hematologic Malignancies Wednesday, October 17 October 17 20, 2018 New York City lymphomaandmyeloma.com

2 For the past 18 years, the Lymphoma & Myeloma Congress has been recognized around the world as the most respected forum for industry-leading hematologic research it s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way. This year, make plans to join us for four days of comprehensive learning as we examine new research, discover innovative treatment methods, and analyze new trends impacting the future of lymphoma, myeloma, and leukemia disorders. CONGRESS CHAIR Morton Coleman, MD Weill Cornell Medicine New York, New York CO-CHAIR, MYELOMA SESSION Ruben Niesvizky, MD Weill Cornell Medicine New York, New York CO-CHAIR, ACUTE LEUKEMIA & HEMATOLOGIC MALIGNANCIES SESSION Gail J. Roboz, MD Weill Cornell Medicine New York, New York CO-CHAIR, LYMPHOMA SESSION John P. Leonard, MD Weill Cornell Medicine New York, New York CO-CHAIR, CLL SESSION Richard R. Furman, MD Weill Cornell Medicine New York, New York REGISTER TODAY: ; INTERNATIONAL:

3 SUPPORT The following companies are supporters of this Congress: GOLD Karyopharm Therapeutics Seattle Genetics Several options are available for companies interested in supporting this Congress. For more information, please contact Imedex by at Lymphoma & Myeloma is genuinely one of the best meetings of the year. The detailed agenda allows for a deep dive into these complex diseases and provides practical advice for the treating clinician. The time allowed for Q&A makes this program unique, facilitating excellent interaction with the faculty, who are truly the leaders in the field. A mix of debates and didactic lectures keeps the audience engaged and encourages outstanding education. ENDORSED BY Joseph Mikhael, MD Chief Medical Officer International Myeloma Foundation REGISTER BY JULY 31, 2018 LYMPHOMAANDMYELOMA.COM

4 This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders. SCIENTIFIC AGENDA NEW APPROACHES IN ACUTE LEUKEMIA & HEMATOLOGIC MALIGNANCIES WEDNESDAY, OCTOBER 17, :30 AM Welcome: Gail J. Roboz, MD Session I: Acute Leukemias 10:40 AM Pre- 10:50 AM Diagnosis and Treatment of Newly Diagnosed ALL 11:10 AM Immunotherapy of ALL 11:30 AM DEBATE: Which Patients Should Be Transplanted for ALL? 12:00 PM Panel Discussion and Post- 12:15 PM Luncheon Programs Session II: MPN & MDS 1:45 PM Pre- 1:55 PM Monitoring Patients on Longstanding TKI Therapy for CML: What to Look for Other Than BCR-ABL 2:15 PM Treatment Strategies for Myelofibrosis 2:35 PM MDS: Is Your Hypomethylator Working? 2:55 PM DEBATE: Which Patients with CML Should Stop TKI Therapy? 3:25 PM Panel Discussion and Post-Debate Audience Survey 3:40 PM Break Session III: Special Topics 4:00 PM Pre- 4:10 PM Newly Diagnosed AML: Hitting the Right Target 4:30 PM AML: What to Do with Your 500-Gene Mutation Report 4:50 PM MRD in AML: What is It and What Do I Do About It? 5:10 PM AML Years: Who Should Get an Allo Transplant? 5:30 PM Panel Discussion and Post- 5:45 PM Session Adjourn 5:45 PM Exhibit Hall/Product Theater Opening REGISTER TODAY: INTERNATIONAL:

5 MYELOMA SESSION THURSDAY, OCTOBER 18, :00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to Myeloma Session: Ruben Niesvizky, MD Session I: Precision Medicine in Myeloma 8:10 AM Pre- 8:20 AM Genomics 101: From Deep Sequencing to Liquid Biopsies 8:40 AM Genomics 102: Clinical Use for Treatment Individualization, Including Double-Hit Myeloma 9:00 AM DEBATE: MRD: Ready for Prime Time? Yes, Is MRD for Novel Agents the Same as for Transplantation? No, MRD Does Inform Length of Induction, Need for Transplant/ Consolidation, Maintenance 9:30 AM Panel Discussion and Post- 9:50 AM Break Session II: Immuno-Oncology 10:10 AM Pre- 10:20 AM Vaccination as a Therapeutic Approach in Myeloma 10:40 AM Anti CD38, SLAMF-7, and BiTE Immunotherapy: Are Immune Therapeutics Ready for the Front Line? 11:00 AM CAR-T: State of the Art and Perspective of a Possible Cure 11:20 AM DEBATE: Is Allotransplant Relevant Today in Myeloma? Yes vs. No 11:50 AM Panel Discussion and Post- Debate Audience Survey 12:10 PM Lunch Session III: Treatment 1:40 PM Pre- 1:50 PM Precursor Disorders in Myeloma: Can We Cure Some? 2:10 PM Management of the Fit Patient: Induction, Which One to Choose, 3 or 4 Drugs 2:30 PM Management of the Unfit and Frail Patient 2:50 PM Panel Discussion and Post- 3:10 PM Break Session IV: Special Lectures 3:30 PM Best Myeloma Abstract Presentation 3:40 PM New Horizons in the Treatment of Relapsed and Refractory Myeloma 4:00 PM The SAAS Foundation for Medical Research Award: Michaeli Award for Contribution to Myeloma 4:10 PM Keynote Lecture: Is Myeloma Curable? 4:40 PM Panel Discussion 4:50 PM Adjourn REGISTER BY JULY 31, 2018 LYMPHOMAANDMYELOMA.COM

6 SCIENTIFIC AGENDA CLL SESSION FRIDAY, OCTOBER 19, :00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to CLL Session: Richard Furman, MD Session V: Small Molecule Inhibitors 8:10 AM Pre- 8:20 AM Update on BTK Inhibitors: Ibrutinib Plus the New Kids on the Block: Are They Better? 8:40 AM Update on PI3K Inhibitors: Idelalisib, Copanlisib, Duvelisib, Umbralisib: Is Toxicity the Key? Session VI: The Future of CLL 10:00 AM Pre- 10:10 AM Update on Chemotherapy in 2018: Is Chemotherapy Passé? 10:30 AM Treatment Options for the Young Patient with Deletion 17p: Do They Need a Different Approach? Session VII: Special Topics in CLL 9:00 AM Update on Venetoclax: How Low Can You Go (MRD)? 9:20 AM Panel Discussion and Post- 9:40 AM Break 10:50 AM Does Sequence Matter for Novel Therapies? 11:10 AM What s Next in CLL? 11:30 AM Panel Discussion and Post- 11:50 AM Session Adjourn 11:50 AM Luncheon Programs 1:20 PM Pre- 1:30 PM Ethnic, Environmental, Genetic, and Familial Risk Factors for CLL 1:50 PM Prince Family Lecture: Small RNAs and Their Role in CLL: Molecular Breakthroughs? 2:10 PM Bruce Waterfall Memorial Lecture: What are the Best Front-Line Therapies for Waldenström Macroglobulinemia? 2:30 PM Bruce Waterfall Memorial Lecture: What are the Newest Therapies for Relapsed Refractory Waldenström Macroglobulinemia? 2:50 PM Post- 3:00 PM Break Session VIII: CLL Transformation 3:20 PM Pre- 3:30 PM Gebroe Family Lecture: Can We Predict Who Will Get Richter s Transformation? 3:50 PM Therapeutic Options for Richter s Syndrome 4:10 PM Where are We with CAR T-Cells in CLL? What are the Data? Does It Work for Transformation? 4:30 PM Panel Discussion and Post- 4:50 PM Adjourn REGISTER TODAY: INTERNATIONAL:

7 LYMPHOMA SESSION SATURDAY, OCTOBER 20, :00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to Lymphoma Session: John Leonard, MD Session IX: Special Topics in Lymphoma 8:10 AM Pre- 8:20 AM Patient-Derived Xenografts (PDX) in Lymphoma: How Can They Help Advance Therapy? 8:40 AM New Targets and Tools in Lymphoma Treatment 9:00 AM Vitamin D in Lymphoma Therapy: What is Its Role, and Should We Supplement? 9:20 AM Panel Discussion and Post- 9:40 AM Break Session X: New Directions in Lymphoma 10:00 AM Pre-Session Survey 10:10 AM DEBATE: What is the Best Upfront Approach for the Treatment of Advanced Stage Hodgkin s Lymphoma? Side 1: A (Brentuximab Vedotin) VD Side 2: A (Bleomycin) VD 10:40 AM DEBATE: Is Obinutuzumab Superior to Rituximab in Lymphoma? Yes vs. No 11:10 AM Auto-Transplant vs. CAR-T: How Should We Sequence Therapy, and Who Should Receive Therapy? 11:30 AM Panel Discussion and Post- Session XI: Immunotherapy in Lymphoma 11:50 AM Presentation of Best Lymphoma Abstract 12:00 PM The SAAS Foundation for Medical Research Award Ceremony 12:10 PM Immunotherapy of Hodgkin s and Non-Hodgkin s Lymphoma 12:40 PM Discussion 12:45 PM Session Adjourn 12:45 PM Luncheon Programs Session XII-A: Breakouts: Indolent and Mantle Cell Lymphoma 2:15 PM Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma 2:35 PM Breakout #2: How I Approach Early Relapsing Follicular Lymphoma 2:55 PM Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma 3:15 PM Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma 3:35 PM Break REGISTER BY JULY 31, 2018 LYMPHOMAANDMYELOMA.COM

8 SCIENTIFIC AGENDA LYMPHOMA SESSION SATURDAY, OCTOBER 20, 2018 Session XII-B: Breakouts: Aggressive and T-Cell Lymphoma (Concurrent with XII-A) 2:15 PM Breakout #5: How Should We Treat Double-Hit and Double- Expressor DLBCL? 2:35 PM Breakout #6: New Drugs for Aggressive Lymphoma 2:55 PM Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment 3:15 PM Breakout #8: Novel Approaches for T-Cell Lymphoma 3:35 PM Break Session XIII-A: Breakouts: Indolent and Mantle Cell Lymphoma 3:55 PM Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma 4:15 PM Breakout #2: How I Approach Early Relapsing Follicular Lymphoma 4:35 PM Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma 4:55 PM Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma 5:15 PM Adjourn Session XIII-B: Breakouts: Aggressive and T-Cell Lymphoma 3:55 PM Breakout #5: How Should We Treat Double-Hit and Double- Expressor DLBCL? 4:15 PM Breakout #6: New Drugs for Aggressive Lymphoma 4:35 PM Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment 4:55 PM Breakout #8: Novel Approaches for T-Cell Lymphoma 5:15 PM Adjourn REGISTER TODAY: INTERNATIONAL:

9 CONCURRENT NURSE PRACTITIONER AND PHYSICIAN ASSISTANT SESSIONS THURSDAY, OCTOBER 18, 2018 Session I: Updates in Multiple Myeloma 8:45 AM Welcome and Introduction of Track: Morton Coleman, MD 8:55 AM Track Overview: Jeremy T. Heinerich, PA-C 9:00 AM Pre- 9:10 AM Role of Immunomodulating Agents in Multiple Myeloma 10:10 AM Break 10:25 AM Role of Transplant in Multiple Myeloma 11:25 AM Interpretation of Bone Marrow Biopsies in Hematologic Malignancies 12:25 PM Post- 12:35 PM Lunch FRIDAY, OCTOBER 19, 2018 Session II: Updates in CLL 8:45 AM Welcome and Introduction of Track: Morton Coleman, MD 8:55 AM Track Overview: Jeremy T. Heinerich, PA-C 9:05 AM Pre- 9:15 AM Managing Toxicities of Oral Therapies in CLL 10:15 AM Break 10:35 AM Role of MRD Negativity in CLL 11:35 AM Post- 11:45 AM Lunch SATURDAY, OCTOBER 20, 2018 Session III: Hands-On Workshops in Lymphoma 8:20 AM Welcome and Introduction of Track: Morton Coleman, MD 8:25 AM Track Overview: Jeremy T. Heinerich, PA-C 8:30 AM Bone Marrow Biopsy Workshop 9:30 AM Lumbar Puncture Workshop 10:30 AM Break 11:00 AM CAR T-Cell in Lymphoma 12:00 PM Hodgkin s Lymphoma Updates 1:00 PM Lunch The concentration of clinical treatment, prognostic, and biologic advances in lymphoma, myeloma, and CLL, as well as how they impact current practice care, is the key strength and takeaway. REGISTER BY JULY 31, 2018 LYMPHOMAANDMYELOMA.COM

10 CONTINUING EDUCATION Physicians Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for AMA PRA Category 1 Credits TM. Maintenance of Certification ABIM MOC Successful completion of this CME activity enables a participant to earn MOC points towards the American Board of Internal Medicine s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. Pharmacy Nursing Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Who Should Attend This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. Learning Objectives Upon successful completion of these educational activities, participants should be better able to:» Interpret efficacy and safety results from recent clinical trials that led to the approval of new pharmacologic agents for the treatment of leukemias, lymphomas, or myeloma» Assess the prognostic impact of molecular biomarkers and genetic mutations that are common to hematologic malignancies» Evaluate the emerging role of immunotherapies as an intervention for hematologic malignancies that are known to have an immunologic component» Devise tailored therapeutic strategies designed to realize optimal therapeutic response from hematologic cancer patients who are either fit or frail» Describe the mechanisms of action of new or emerging treatments that are designed to target molecular biomarkers or genetic aberrations that are frequently observed in hematologic cancers» Assess both established and recently pioneered sequencing and combination strategies for second-line or salvage therapy interventions EXHIBITORS Exhibit space is available for companies interested in exhibiting at this Congress. For more information, please contact Imedex at or exhibits@imedex.com. REGISTER TODAY: INTERNATIONAL:

11 Congress Location and Accommodations Sheraton New York Times Square Hotel 811 W. 7th Avenue New York, New York Special Room Rate: $324/night plus tax Reserve Your Room Online at: aws.passkey.com/go/imedex2018 REGISTRATION RATES EARLY Through 7/31/18 DISCOUNTED 8/1/18 9/14/18 REGULAR/ ONSITE 9/15/18 10/20/18 Physician, Pharmacist, and Non-Clinician Researcher $549 $349 $749 Physician Assistant, Nurse Practitioner $349 $399 $449 Nurse, Fellow, Resident, Student, Trainee Pharmaceutical Personnel $199 $249 $299 $899 Register by July 31, 2018 to secure your place at the best rate. Register online at lymphomaandmyeloma.com or call (US) (INTL) REGISTER BY JULY 31, 2018 LYMPHOMAANDMYELOMA.COM

12 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009, USA October 17 20, 2018 New York, NY Register by July 31 to reserve your seat at the best rate. lymphomaandmyeloma.com